Approximately 13% 37% of patients with lung cancer who receive radical radiotherapy suffer symptomatic radiation pneumonitis [1] , which causes great harm to patients and limits increases in radiation doses. At present, several studies suggest that transforming growth factor茁 1 (TGF茁 1) is correlated with radiationinduced lung injury, but the peripheral serum levels of TGF茁 1 only reflect the immune status of the lung indirectly.
Approximately 13% 37% of patients with lung cancer who receive radical radiotherapy suffer symptomatic radiation pneumonitis [1] , which causes great harm to patients and limits increases in radiation doses. At present, several studies suggest that transforming growth factor茁 1 (TGF茁 1) is correlated with radiationinduced lung injury, but the peripheral serum levels of TGF茁 1 only reflect the immune status of the lung indirectly. Biopsy or lung lavage ca n directly reflect the immune status of the lung, but they are invasive and painful procedures with poor clinical feasibility. Induced sputum can collect cell and liquid components of lower respiratory tract secretions, and compared to lung lavage and biopsy, it is relatively more secure, reliable, simple, free from the restrictions of the disease, and more accessible to patients. In this study, TGF茁 1 in induced sputum and serum was detected to predict radiation pneumonitis and provide a noninvasive, safe, and reliable method.
Inclusion criteria: Patients with pathologically confirmed nonsmall cell lung cancer (NSCLC) who received threedimensional conformal radiation therapy (3DCRT) were included. Their expected survival time was 逸 6 months, Karnofsky Performance Status (KPS) score was 逸 80 points, and those who were willing to participate were included.
Exclusion criteria: Patients with IVstage or widespread metastatic disease, history of lung surgery, history of chest radiation, asthma, severe chronic bronchitis, emphysema, pulmonary heart disease, severe lung infection or other serious illnesses, such as myocardial infarction in the past 6 months, were excluded.
Between November 2007 and January 2009, 23 patients enrolled, of whom 20 (87.0% ) were men and 3 (13.0% ) were women, with ages of 4274 years, and a median age of 65 years. Of these patients, 20 had squamous cell carcinoma (87.0% ), 3 had adenocarcinoma (13.0% ). A total of 20 had central types (87.0% ) and 3 peripheral types (13.0% ), 14 had IIIastage disease (60.9%), and 9 had IIIbstage disease (39.1%). A total of 12 (52.2% ) had a history of smoking, and 11 (47.8% ) were nonsmokers. Eighteen (78.3% ) received chemotherapy and 5 (21.7%) had not.
Prescribed dose to a planning target volume (PTV) of all patients was more than 50 Gy, 1.82.0 Gy/fraction, once a day, 5 days/week. 3DCRT or intensity modulated radiation therapy (IMRT) was performed. The gross tumor volume (GTV) of the primary lung tumor was outlined in the lung window. Metastatic lymph nodes (GTV nd ) were outlined in mediastinal windows (CT display). A total of 8 mm around GTV and the area involved with swollen lymph nodes were defined as the clinical target volume (CTV). CTV that extended outside 510 mm was defined as PTV. The V 20 of lungs was 臆 30% , V 30 臆 20% . The spinal cord dose of 0 volume was 臆 45 Gy/6 weeks. The V 40 of the heart was 臆 50%. Dithiothreitol (DTT) was purchased from SigmaAldrich (USA). TGF茁 1 antibodies were purchased from Beijing Boao Sen BioTechnology Co., Ltd. The TGF茁 1 enzymelinked immunosorbent assay (ELISA) kit was purchased from Xin Bo Sheng BioTechnology Co., Ltd.
Before radiotherapy and near the end of radiotherapy, the 5mL samples of fasting blood were collected with ethylenediaminetetraacetic acid (EDTA) tubes from the cubital vein, refrigerated in 4益 , centrifuged under 4益 within 12 h, and 1007 伊 for 10 min. The supernatant fluid was cryopreserved on standby at 20益 and thawed at room temperature when the detection of TGF茁 1 cytokines was performed in 2 h. Quantitative determination was performed by the doubleantibody sandwich method of ELISA. Operations were in strict accordance with specification requirements.
Before and near the end of radiotherapy, atomization was performed to induce sputum. First, patients cleaned the mouth and pharynx, inhaled 4% hypertonic saline through an ultrasonic spray machine, then coughed deeply, and collected the sputum in a clean container. The cumulative spray time was not more than 30 min. About 1 mL of coughinduced sputum was collected and < 10 squamous epithelial cells in each low power field was considered qualified sputum [2] . The sticky portion of the qualified sputum was taken into a tube, then an equal volume of 1% DTT was added and mixed, incubated at 37益 for 10 min, and oscillated 35 min to make it homogeneous. Using a 100mesh filter to remove impurities, 895N was centrifuged for 20 min at room temperature and the deposition was smeared. For each specimen, several sheets of deposition smear were prepared and fixed with 4% paraformaldehyde, dried, and stored at 20益 , to prepare for the inspection of TGF茁 1. Instructions were strictly carried out in all streptavidinperoxidase (SP) immunocytochemical staining.
The diagnostic criteria for immunocytochemical staining included the following. Five views of each sheet were taken randomly to count the cells. Macrophages with diffuse brownstained particles of cytoplasm were regarded as positive cells. The numbers of positive cells were rated as follows: 0 was (), < 25% was (+), 25%50% was (++), and > 50% was (+++), with ++ or more regarded as positive.
From the beginning for radiotherapy to 3 months after radiotherapy, acute radiation pneumonia was evaluated every week according to Radiation Therapy Oncology Group (RTOG) standards. SPSS version 13.0 was used for statistical analysis. A test was used to compare the mean, and 字 2 test and Fisher exact test were used to compare the rate.
The followup deadline of this group of patients was January 30, 2009. The shortest followup time was 3 months and the longest 13.5 months, with a median followup time of 7 months. No patients were lost to follow. During the followup period, the overall incidence of acute radiation pneumonia was 39.13% (9/23), and the incidence of Grade2 and above radiation pneumonitis in patients was 30.43% (7/23). Of the patients with acute radiation pneumonia, 2 had Grade1 disease, 6 had Grade2 disease, 1 had Grade3 disease, and 0 had Grade4 disease. Regarding shortterm effect, we observed complete response (CR) in 3 patients (13.04% ), partial response (PR) in 16 patients (69.57% ), stable disease (SD) in 2 patients (8.70% ), and progressive disease (PD) in 2 patients (8.70% ). The overall response rate (CR + PR) was 82.61%.
Before radiotherapy, levels of serum TGF茁 1 in 2 patients were not detected due to hemolysis, and in the rest of the group, the serum TGF茁 1 levels were 442.2011 280.00 pg/mL, with a mean of 1679.36 pg/mL and a median of 605.00 pg/mL (set as a base level for reference value of this study). At the end of radiation therapy, serum TGF茁 1 levels were 280.112 840.0 pg/mL, with a mean of 2170.6 pg/mL and median of 677.5 pg/mL. There was an increasing trend compared with values before the radiotherapy, however, no statistical significance existed ( = 0.139).
Patients whose serum TGF茁 1 levels were higher than that of normal patients before radiotherapy had an incidence of radiation pneumonitis of 30.0% (3/10), and the incidence of radiation pneumonitis in normal patients was 54.5% (6/11). There were no statistical differences ( = 0.387). The incidence of radiation pneumonitis for patients with elevated levels of serum TGF茁 1 after radiotherapy was 45.5% (5/11), and there was no significant difference ( = 1.000) compared with 40.0% of patients without elevated TGF茁 1 levels (4/10) ( Table 1) .
Excluding one patient who was unable to induce sputum, the remaining 22 patients were successful in inducing sputum, which was adapted for parallel detection of TGF茁 1 in sputum. According to immunocytochemical staining, positive expressions of TGF茁 1 were detected as brownish yellow in sputum, located in the cytoplasm of macrophages and epithelial cells, with macrophages being the main contributor (Figure 1 ).
Before radiotherapy, 6 patients (27.3% ) had positive expressions of TGF茁 1 in sputum. At the end of radiotherapy, 15 patients (68.2% ) had positive expression, which illustrates a significant increase compared with the positive rate before radiotherapy ( = 0.015). Radiation pneumonitis occurred in 33.3% patients with TGF茁 1positive expression in sputum before radiotherapy (2/6), and occurred in 37.5% patients with negative expression (6/16), yet there was no statistical difference ( = 1.000). The incidence of radiation pneumonitis was 46.7% in patients with positive TGF茁 1 expression in sputum after radiotherapy (7/15) and 14.3% in patients with negative TGF茁 1 expression in sputum (1/7), yet no significant difference was demonstrated ( = 0.193) ( Table 1) .
Of the 4 patients without chemotherapy treatment, 2 (50.0%) had positive TGF茁 1 expression in sputum, and of the 18 patients that received chemotherapy, 13 (72.2% ) had positive TGF茁 1 expression in sputum after radiotherapy, yet there were no significant differences ( = 0.565). The analysis of radiotherapeutic dose on bilateral normal lungs in both groups with TGF茁 1 positive and negative expression in sputum after radiotherapy are shown in Table 2 .
The expression of TGF茁 1 in sputum was detected in 54.5% (6/11) patients with elevated levels of serum TGF茁 1 after radiotherapy, and 80.0% (8/10) in patients with reduced serum TGF茁 1 levels after radiotherapy, but there were no significant differences ( = 0.354). When trying to predict radiation pneumonitis from serum and sputum levels of TGF茁 1, no TGF鄄 茁 1 expression in induced sputum examined by immunocytochemistry of the streptavidin鄄 peroxidase (SP) method significant differences were found among the subgroups ( = 0.866) (Table 3 ).
Elevated serum TGF茁 1 levels were detected in 42.1% (8/19) of patients with shortterm treatment efficacy, and 75.0% (3/4) in patients with no treatment response. The incidence rate of radiation pneumonitis was 50% in patients with treatment response and elevated serum TGF茁 1 levels, and 33.3% in patients with no treatment response and elevated serum TGF茁 1 levels ( = 0.792) ( Table 4 ).
The development process of radiationinduced lung injury includes injuries of alveolar epithelial and endothelial cells, the expression of inflammatory cytokines, fibroblast proliferation, and fiber matrix synthesis. This process is achieved through a series of cells and the expression, conduct, amplification, feedback, and adjustment of cell signaling [45] . Recent research has indicated that TGF茁 1 might be correlated with radiation pneumonitis, and researchers have tried to evaluate the level of serum TGF茁 1 to predict radiation pneumonitis, however, the results have been inconsistent. Zhao .
[6] monitored serum TGF茁 1 in 26 patients with stages IIII NSCLC before radiotherapy, 2 weeks and 4 weeks after the start of radiotherapy, and at the end of radiotherapy. The difference from their absolute value was not obvious. But in the fourth week of radiotherapy, the TGF茁 1 ratio was different between patients with acute radiation pneumonitis and without. At 4 weeks after radiotherapy, a TGF茁 1 ratio greater than 2.0 predicted radiation pneumonitis with 66.7% accuracy and 95.0% specificity. Vujaskovic .
[7] researched conventional radiotherapy in 27 patients with lung cancer, and found that radiation pneumonitis occurred in 9 patients with obviously higher than average levels of serum TGF茁 1, while serum TGF茁 of other patients remained stable or declined. In addition, TGF茁 1 levels in patients with treatment response was low or normal. Nova kovaJiresova . [8] observed that basic serum TGF茁 1 levels were not different between patients with radiation pneumonitis and without after radiotherapy, but the serum TGF茁 levels of the former had an upward trend during radiotherapy, and the latter had a downward trend. This study also showed that at the end of radiotherapy, patients with elevated serum TGF茁 1 had higher rates of radiation pneumonitis than patients with decreased serum TGF茁 1, but no significant difference was detected. This was possibly because of the small sample size, so further studies with larger sample sizes are needed.
Detecting TGF茁 1 levels in peripheral blood serum is an indirect way to reflect the immune status of the lung. Alveolar lavage or lung biopsy are direct ways, by detecting cytokine secretion. In 1992, by studying changes in the levels of TGF茁 1 in the irradiated rabbit bronchoalveolar lavage fluid, Rubin et al.9 first proposed that radiationinduced lung injury was caused by a complex interaction of multiple cytokines. Barthelemy .
[10]
studied the TGF茁 1 levels in different parts of bronchoalveolar lavage fluid (BALF) before and after radiotherapy in 11 patients who received radiotherapy for lung cancer and found that TGF茁 1 and IL6 levels increased significantly in the BALF of the target area after radiotherapy. In addition, it was especially high in patients with severe radiation pneumonitis, while TGF茁 1 levels in BALF beyond the target area remained unchanged both before and after radiotherapy. So it was thought that these cytokines had an important role in the occurrence of radiation pneumonitis. However, bronchoalveolar lavage is an invasive procedure, which causes pain for patients and thus has poor value in clinic. Sputum is the mucus from the surface of the lower respiratory tract, and is generally used as samples for clinical diagnosis, assessment of treatment effect, and scientific research. Compared with BALF, induced sputum samples are rich, easy to concentrate and repeat, and safer. Plus, sputum is more representative as a secretion product from numerous proximal branches of the airway than BALF or bronchial washing fluid (BWF) because it is a natural concentrated product of the central respiratory tract. As liquidphase indicators, BALF and BWF need to be rinsed with large volumes of normal saline, with the inevitable exchange of alveolar and blood components, and thus most of the chemical composition is lower than in sputum. BALF needs to be concentrated several times to detect some components, while sputum needs not. Compared with peripheral blood, inflammatory indicators in sputum are more direct and more sensitive [11] . Currently, measurement levels of TGF茁 1 in sputum sediment is mainly used in the study of children with asthma. According to reports, the positive expression of TGF茁 1 has been detected in the induced sputum of children with asthma, while no positive expression was found in the normal control group [12] . So far, no reports have been published that try to predict The data of TGF鄄 茁 1 levels were unaviliable for two patients. radiation injury by detecting TGF茁 1 levels in induced sputum. In this study, the positive expression of TGF茁 1 was found in the sputum of patients with lung cancer by immunocytochemical staining, mainly located in macrophages and occasionally located in epithelial cells, which was inconsistent with the results in the literature. We also found that radiation pneumonitis was higher for patients with positive TGF茁 1 expression than those with negative expression on the slides of sputum sediment after radiotherapy.
Generally, peripheral blood TGF茁 1 levels in healthy humans is low, and when lung tissue is exposed to radiation, because excessive TGF茁 1 leaks into circulating blood, peripheral blood TGF茁 1 levels increase. This study found that sputum TGF茁 1 expression levels after radiotherapy tended to be higher than its expression before radiotherapy as serum TGF茁 1, but it was not statistically significant. It was found that after radiotherapy, TGF茁 1 was expressed in sputum in 54.5% (6/11) of patients with elevated levels of serum TGF茁 1, and in 80.0% (8/10) of patients with reduced levels of serum TGF茁 1, but there was no significant difference ( = 0.354).
There might be reasons for this phenomenon.
(1) Peripheral blood TGF茁 1 levels were detected by quantitative ELISA methods, which are more sensitive than the qualitative immunocytochemistry used for sputum. (2) During measurement, peripheral TGF茁 1 might become elevated, because platelet degranulation during the procedure could release TGF茁 1 [13] . (3) In this study, sputum TGF茁 1 expression levels were only qualitative in the expression in macrophages, but some TGF茁 1 expression in the peripheral blood were from tumor cells [7, 14] . As the tumor shrunk after radiotherapy, tumor cells had less impact on levels of TGF茁 1 in the peripheral blood.
This study showed 47.06% of patients with effective treatment had elevated serum TGF茁 1, while 75.00% of patients with ineffective treatment had elevated serum TGF茁 1 ( = 0.586). The incidence rate of radiation pneumonitis for patients with effective treatment and elevated serum TGF茁 1 was 50.00%, and in patients with ineffective treatment and elevated serum TGF茁 1, the incidence of radiation pneumonitis was 33.33% ( = 0.792). This might explain why the incidence of radiation pneumonitis was not elevated in patients with higher preradiotherapy serum TGF茁 1 levels than normal patients, while the incidence of radiation pneumonitis was higher in patients with both higher serum TGF茁 1 levels at the end of radiotherapy, and positive TGF茁 1 expression on sputum sediment slides after radiotherapy. But the results did not achieve statistical significance, which might be due to the small sample size. So the sample size needs to increase for further study.
There are many factors affecting the incidence of radiation pneumonitis. Patients with fundamental lung disease were excluded from this study. As for the two groups with positive and negative TGF茁 1 expression in sputum, no difference existed in the normal amount of bilateral lung exposure dose. In addition, there was no significant difference between the two groups in patient history of chemotherapy. In a word, we tried to minimize the effects as much as we could. If the expression of TGF茁 1 in sputum could be applied to predict radiation pneumonitis, its application would provide a noninvasive, reliable, and convenient new method for predicting radiation pneumonitis.
With an indepth understanding of the role and status of TGF茁 1 in radiationinduced lung injury, and if a clear biologic basis of the responsive factors to the toxicity of radiation is achieved, individualized and specially measured radiotherapy for the treatment of patients with lung cancer might be achieved, so that the rate of longterm survival may be raised by improving the rate of local control.
